Nasdaq: ARWRArrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals: results and news

    Every Arrowhead Pharmaceuticals filing with the US SEC that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings.

    1 article · Health Care · Latest 13 Nov 2026

    Assorted tablets and capsules in white, pink, yellow, blue and orange

    Nasdaq: ARWRArrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals Q4 FY2026 Results: Net Loss $724 Million on Revenue of $451 Million

    Arrowhead Pharmaceuticals (Nasdaq: ARWR) reported results for its 2026 fiscal year ended 30 Sep 2026, with GAAP revenue of $450.8 million and a GAAP net loss attributable to the company of $724.2 million, it said on 12 Nov 2026. Diluted loss per share (GAAP) was $5.11. The release gives no adjusted (non-GAAP) figures.

    • US stocks
    • Earnings

    Blacklitt Research3 min read